

# MDCO 2Q 2010 Conference Call Summary

## *Highlights*

- Aim to be leaders in acute and intensive care medicine worldwide
  - 2,650 targeted leading hospitals
  - 25 countries
  
- Angiomax<sup>®</sup>/Angiox<sup>®</sup> (bivalirudin) volume growth
  - 1H10 international revenue up 48% compared to 1H09
  - 2Q Angiox European sales in MDCO operating units
    - 55% increase in volume
    - 45% in net sales
    - Includes Italy, France, Scandinavia, Benelux, UK, Germany
  - U.S. hospital purchases of Angiomax this quarter: 190,000 vials
  
- Portfolio
  - 2 marketed products:
    - Angiomax/Angiox
    - Cleviprex<sup>®</sup>
  - 3 in Phase 3 or registration
    - Argatroban ready to use formulation
    - Cangrelor
    - Oritavancin
  - 2 in early stage clinical trials
    - ApoA-I Milano
    - CU2010
  - Discovery centers Leipzig, Montreal

This document is intended to assist listeners of The Medicines Company's quarterly results conference call available via webcast at [www.themedicinescompany.com](http://www.themedicinescompany.com). In this document and the call, statements about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, including our 2009 guidance, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, our ability to develop our global operations and penetrate foreign markets, whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether the Company will make regulatory submissions for product candidates on a timely basis, whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, whether physicians, patients and other key decision makers will accept clinical trial results, risks associated with the establishment of international operations, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on May 10, 2010, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.